Clinical Trials
32 trialsMK-3475-G21
Merck Sharp & Dohme LLC
MK-3475-051
Merck Sharp & Dohme LLC
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
SELECT-CAR-NK
Essen Biotech
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Columbia University
PIVOT IO 020
Bristol-Myers Squibb
PDX+Romi
Columbia University
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Northwestern University
Bu Flu TBI
OHSU Knight Cancer Institute
LCCC0510
UNC Lineberger Comprehensive Cancer Center
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
PCYC-0403
Pharmacyclics LLC.
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
National Cancer Institute (NCI)
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
M.D. Anderson Cancer Center
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
Northwestern University
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
Northwestern University
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Fred Hutchinson Cancer Center
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Pfizer